News
NRXP
2.280
-6.56%
-0.160
Psychedelic: Definium Therapeutics narrows quarterly net loss
TipRanks · 9h ago
MeiraGTx Holdings PLC (MGTX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 11h ago
NRX Pharmaceuticals (NRXP) Gets a Buy from BTIG
TipRanks · 13h ago
NRX Pharmaceuticals Is Maintained at Buy by BTIG
Dow Jones · 14h ago
NRX Pharmaceuticals Price Target Raised to $12.00/Share From $10.00 by BTIG
Dow Jones · 14h ago
NRx Pharmaceuticals commences selling of preservative-free ketamine
TipRanks · 1d ago
NRX Pharmaceuticals (NRXP) Receives a Buy from H.C. Wainwright
TipRanks · 3d ago
Weekly Report: what happened at NRXP last week (1102-1106)?
Weekly Report · 3d ago
Psychedelic: Compass Pathways beats Q3 loss estimate
TipRanks · 11/05 15:50
Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), COMPASS Pathways (CMPS) and NRX Pharmaceuticals (NRXP)
TipRanks · 11/04 15:41
NRx Pharmaceuticals Gains FDA Approval for Preservative-Free Ketamine
TipRanks · 11/02 13:35
Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday
Benzinga · 11/02 13:26
NRX Pharmaceuticals Is Maintained at Buy by Ascendiant Capital
Dow Jones · 11/02 09:57
NRX Pharmaceuticals Price Target Raised to $51.00/Share From $50.00 by Ascendiant Capital
Dow Jones · 11/02 09:57
Weekly Report: what happened at NRXP last week (1026-1030)?
Weekly Report · 11/02 09:52
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $51
Benzinga · 11/02 09:48
NRX Pharmaceuticals (NRXP) Receives a Buy from BTIG
TipRanks · 11/02 01:35
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/30 12:05
NRx Pharma rises on FDA nod for generic ketamine injection
Seeking Alpha · 10/30 11:39
NRx Pharmaceuticals announces FDA approval for Ketamine ANDA
TipRanks · 10/30 11:11
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.